

Hutchison Whampoa Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 013)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

Executive Directors:

Mr. LI Ka-shing (*Chairman*)
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr. FOK Kin-ning, Canning
Mrs. CHOW WOO Mo Fong, Susan
Mr. Frank John SIXT
Mr. LAI Kai Ming, Dominic
Mr. KAM Hing Lam

Non-executive Directors:

Mr. George Colin MAGNUS
Mr. William SHURNIAK

Independent Non-executive Directors:

The Hon. Sir Michael David KADOORIE
Mr. Holger KLUGE
Mr. William Elkin MOCATTA
*(Alternate to The Hon. Sir Michael
David Kadoorie)*
Mr. Simon MURRAY
Mr. OR Ching Fai, Raymond
Mr. WONG Chung Hin
(also Alternate to Mr. Simon Murray)

Hong Kong, 12 April 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)**

**Annual Report and Accounts 2006
Notice of Annual General Meeting**

London, Thursday, 12 April 2007: Chi-Med today announces that its Annual Report and Accounts for the year ended 31 December 2006 together with the Notice of Annual General Meeting ("AGM") and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).

The AGM of Chi-Med will be held at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY on Friday, 11 May 2007 at 2:30 p.m.

Ends

Enquiries

Chi-Med

Telephone: +852 2121 8200

Christian Hogg, CEO

Citigate Dewe Rogerson

Telephone: +44 (0) 20 7638 9571

Anthony Carlisle

+44 (0) 7973 611 888

Yvonne Alexander

+44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.